Dare Bioscience Inc (DARE) USD0.0001

Sell:$3.02Buy:$3.03$0.06 (1.85%)

Prices delayed by at least 15 minutes
Sell:$3.02
Buy:$3.03
Change:$0.06 (1.85%)
Prices delayed by at least 15 minutes
Sell:$3.02
Buy:$3.03
Change:$0.06 (1.85%)
Prices delayed by at least 15 minutes

Company Information

About this company

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.

Key people

Sabrina Martucci Johnson
President, Chief Executive Officer, Principal Financial Officer, Company Secretary, Director
William H. Rastetter
Independent Chairman of the Board
Cheryl Renee Blanchard
Independent Director
Jessica D. Grossman
Independent Director
Susan L. Kelley
Independent Director
Gregory W. Matz
Independent Director
Click to see more

Key facts

  • EPIC
    DARE
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US23666P2002
  • Market cap
    $26.29m
  • Employees
    21
  • Shares in issue
    8.85m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.